Women will be assigned to one of two groups; Group one will receive ‘standard high risk care’ and Group two will receive ‘standard high risk care’ and enoxaparin 40 mg sc (Clexane®, Sanofi-Aventis) [42] daily from recruitment (at gestational age >6+0 and <16+0 weeks) until 36...
Enoxaparin was administered (40 mg subcutaneous (SC) if BMI ≤50 kg/m2 or 60 mg SC if BMI >50 kg/m2) for prevention of venous thromboembolism every 12 h starting after induction of anesthesia until discharge. Plasma anti-factor Xa activity was assessed over 12 h after the ...
We tried to identify mechanisms by which sepsis-induced pathophysiological changes may influence the effectiveness of subcutaneously (SC) administered enoxaparin 40 mg once daily. A total of 16 patients (8 men, 8 women; age 35-83 years) meeting the inclusion criteria of severe sepsis were ...
Patients randomized to receive enoxaparin in the acute phase receive fixed-dose SC enoxaparin (60 mg every 12 hours for patients 鈮 65 kg, 40 mg every 12 hours for patients <65 kg). Patients randomized to receive UFH in the acute phase receive SC placebo injections during the chronic phase...
In this prospective FINESSE substudy, centers pre-specified use of either enoxaparin (0.5 mg/kg intravenous [IV], 0.3 mg/kg subcutaneous [SC]) or UFH (40 U/kg IV, 3,000 U maximum) with PCI. A logistic-regression model and a propensity multivariate model, both adjusted for baseline ...
Platelets were 85000/mm3 on the 32nd day, 77000/mm3 on the 34th day, and 61000/mm3 on the 44th day; the coagulation profile, troponin, and liver and kidney function tests remained within the reference range, and no schistocytes were found on repeated peripheral blood smears. On the ...